Nancy A. Simonian - 01 Dec 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
01 Dec 2023
Net transactions value
$0
Form type
4
Filing time
05 Dec 2023, 17:23:22 UTC
Previous filing
02 Nov 2023
Next filing
15 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Disposed to Issuer -7,500 -100% 0 01 Dec 2023 Common Stock 7,500 $121.70 Direct F1, F2
transaction SYRS Stock Option (right to buy) Disposed to Issuer -17,499 -100% 0 01 Dec 2023 Common Stock 17,499 $109.00 Direct F1, F2
transaction SYRS Stock Option (right to buy) Disposed to Issuer -28,001 -100% 0 01 Dec 2023 Common Stock 28,001 $100.90 Direct F1, F2
transaction SYRS Stock Option (right to buy) Disposed to Issuer -29,399 -100% 0 01 Dec 2023 Common Stock 29,399 $75.40 Direct F2, F3
transaction SYRS Stock Option (right to buy) Disposed to Issuer -30,399 -100% 0 01 Dec 2023 Common Stock 30,399 $114.10 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 The option was canceled by mutual agreement of the reporting person and the issuer pursuant to the terms of the Retirement and Transition Agreement, dated September 28, 2023, by and between the reporting person and the issuer, a copy of which was filed on November 14, 2023 as Exhibit 10.1 to the issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023.
F3 This option vested as to 25% of the shares on February 28, 2021, with the remainder vesting in equal monthly installments thereafter through February 28, 2024.
F4 This option vested as to 25% of the shares on February 28, 2022, with the remainder vesting in equal monthly installments thereafter through February 28, 2025.

Remarks:

Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.